Join our community of smart investors

The Aim 100 2024: 40 to 31

The Aim 100 2024: 40 to 31
The Aim 100 2024: 40 to 31Published on November 7, 2024

40. Marlowe

Marlowe (MRL) belongs within that cohort of Aim companies that thrive on tightening regulatory strictures. In Marlowe’s case, this historically meant the broad frameworks governing safety and regulatory compliance. 

However, the shape of the business narrowed midway through the year after it hived off certain governance, risk and compliance software and services assets; following a demerger, its occupational health business Optima Health (OPT) was admitted to Aim. This leaves the focus on business-critical service markets linked to testing, inspection and certification. Management maintains that this area of the compliance market provides the clearest route towards “highly recurring revenues based on non-discretionary customer spend and underpinned by regulatory and insurance requirements”. 

This is subscriber only content
Start your trial to keep reading
PRINT AND DIGITAL

Get 12 weeks for £12
  • Essential access to the website and app
  • Magazine delivered every week
  • Investment ideas, tools and analysis
Already a subscriber? Sign in